$KRTL Biotech to Expand Pain Management Reach into
Post# of 26
(Total Views: 29)
Posted On: 10/16/2025 1:05:52 PM
$KRTL Biotech to Expand Pain Management Reach into U.S. and Global Healthcare Markets
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=496198
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today announced that its subsidiary, KRTL Biotech, Inc., is highlighting its portfolio of pain management pharmaceuticals, one of the most widely utilized and clinically essential categories in the Company’s international product portfolio.
The product line, developed in partnership with Industria Químico-Farmacéutica SIGMA Corp., includes both prescription and over-the-counter formulations for the relief of acute and chronic pain, inflammation, fever, and musculoskeletal discomfort. These therapies serve a broad range of clinical and community healthcare settings across Latin America.
"Pain relief is one of the most immediate and pressing needs in global healthcare, especially in lower-resource settings," said Daniel Bishop, CEO of KRTL Biotech. "By making effective and affordable analgesics widely available, we’re supporting functional wellness and improving quality of life."
Key Formulations in the Pain Management Line:
Analgesics and Antipyretics: Acetaminophen, Ibuprofen, Dipyrone
NSAIDs: Diclofenac (oral, injectable, gel), Meloxicam, Naproxen, Ketoprofen
Combination Therapies: Multimodal relief with muscle relaxants or caffeine
Topical Pain Relief: Anti-inflammatory creams and gels
Together, these options offer clinicians, pharmacists, and patients access to dependable pain relief in diverse care settings.
These formulations are manufactured under certified GMP in Bolivia and are distributed through public health systems and private retail channels across Latin America in primary care, hospitals and emergency settings. SIGMA generated in excess of $600,000 in revenues from these products in its fiscal year ended March 31, 2025.
"Our pain management line reflects SIGMA’s decades-long commitment to health equity in Bolivia," said Patricia Wilstermann, CEO of SIGMA. "We’ve built trust in the market through consistent product quality and availability—something we are proud to bring to KRTL’s global expansion strategy."
KRTL Biotech is currently evaluating regulatory entry strategies for select analgesics and NSAIDs in the U.S., including potential alignment with the OTC Monograph system for over-the-counter pain relief and ANDA submissions for prescription NSAIDs. The Company is also exploring opportunities to support global procurement initiatives focused on essential medicines.
“Pain is a universal experience, and so is the need for timely, effective treatment," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Through our partnership with SIGMA, we’re strengthening the supply chain for essential medicines that directly impact people’s daily lives."
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=496198
KRTL Holding Group Inc. (OTC: KRTL) ("KRTL Holding" or the "Company"
today announced that its subsidiary, KRTL Biotech, Inc., is highlighting its portfolio of pain management pharmaceuticals, one of the most widely utilized and clinically essential categories in the Company’s international product portfolio. The product line, developed in partnership with Industria Químico-Farmacéutica SIGMA Corp., includes both prescription and over-the-counter formulations for the relief of acute and chronic pain, inflammation, fever, and musculoskeletal discomfort. These therapies serve a broad range of clinical and community healthcare settings across Latin America.
"Pain relief is one of the most immediate and pressing needs in global healthcare, especially in lower-resource settings," said Daniel Bishop, CEO of KRTL Biotech. "By making effective and affordable analgesics widely available, we’re supporting functional wellness and improving quality of life."
Key Formulations in the Pain Management Line:
Analgesics and Antipyretics: Acetaminophen, Ibuprofen, Dipyrone
NSAIDs: Diclofenac (oral, injectable, gel), Meloxicam, Naproxen, Ketoprofen
Combination Therapies: Multimodal relief with muscle relaxants or caffeine
Topical Pain Relief: Anti-inflammatory creams and gels
Together, these options offer clinicians, pharmacists, and patients access to dependable pain relief in diverse care settings.
These formulations are manufactured under certified GMP in Bolivia and are distributed through public health systems and private retail channels across Latin America in primary care, hospitals and emergency settings. SIGMA generated in excess of $600,000 in revenues from these products in its fiscal year ended March 31, 2025.
"Our pain management line reflects SIGMA’s decades-long commitment to health equity in Bolivia," said Patricia Wilstermann, CEO of SIGMA. "We’ve built trust in the market through consistent product quality and availability—something we are proud to bring to KRTL’s global expansion strategy."
KRTL Biotech is currently evaluating regulatory entry strategies for select analgesics and NSAIDs in the U.S., including potential alignment with the OTC Monograph system for over-the-counter pain relief and ANDA submissions for prescription NSAIDs. The Company is also exploring opportunities to support global procurement initiatives focused on essential medicines.
“Pain is a universal experience, and so is the need for timely, effective treatment," said Cesar Herrera, CEO of KRTL Holding Group Inc. "Through our partnership with SIGMA, we’re strengthening the supply chain for essential medicines that directly impact people’s daily lives."
(0)
(0)